Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

VBI Vaccines Inc. (VBIV)

0.3247   0.012 (3.94%) 03-22 15:02
Open: 0.31 Pre. Close: 0.3124
High: 0.35 Low: 0.31
Volume: 421,301 Market Cap: 92(M)

Technical analysis

as of: 2023-03-22 2:51:49 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 0.51     One year: 0.66
Support: Support1: 0.23    Support2: 0.19
Resistance: Resistance1: 0.44    Resistance2: 0.56
Pivot: 0.36
Moving Average: MA(5): 0.31     MA(20): 0.39
MA(100): 0.51     MA(250): 0.79
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 22.1     %D(3): 12.3
RSI: RSI(14): 33.1
52-week: High: 1.86  Low: 0.23
Average Vol(K): 3-Month: 933 (K)  10-Days: 998 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VBIV ] has closed above bottom band by 30.8%. Bollinger Bands are 21.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.32 - 0.32 0.32 - 0.32
Low: 0.23 - 0.23 0.23 - 0.23
Close: 0.31 - 0.31 0.31 - 0.32

Company Description

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Headline News

Mon, 20 Mar 2023
VBI Vaccines Inc. (VBIV) Shares Down Despite Recent Market ... - The News Heater

Mon, 13 Mar 2023
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates - Zacks Investment Research

Mon, 13 Mar 2023
North American Morning Briefing : Investors Digest -3- -

Mon, 13 Mar 2023
VBI Vaccines Reports Full Year 2022 Financial Results - VBI Vaccines

Mon, 06 Mar 2023
North American Morning Briefing : Focus This Week -3- -

Thu, 23 Feb 2023
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst ... - VBI Vaccines

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 258 (M)
% Held by Insiders 1.9148e+008 (%)
% Held by Institutions 0.5 (%)
Shares Short 11,850 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -7.924e+007
EPS Est Next Qtl -0.24
EPS Est This Year -0.89
EPS Est Next Year -1.01
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -9
Return on Assets (ttm) 339.4
Return on Equity (ttm) -25.7
Qtrly Rev. Growth 870000
Gross Profit (p.s.) 103.86
Sales Per Share -48.13
EBITDA (p.s.) -5.36508e+006
Qtrly Earnings Growth -0.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -73 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.89

Stock Dividends

Dividend 0
Forward Dividend 1.291e+007
Dividend Yield 0%
Dividend Pay Date 2012-12-27
Ex-Dividend Date 2012-02-04
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.